The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.

AstraZeneca and partner Daiichi’s drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer in January and for EGFR-mutated non-small cell lung cancer (NSCLC) in June this year. Datroway ...

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

Milestone Pharmaceuticals Inc. is a strong buy under $2 with FDA approval for Cardamyst expected in 2026, offering unique ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...

By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.